These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 15682286)

  • 21. Cost-effectiveness of primary cytology and HPV DNA cervical screening.
    Bistoletti P; Sennfält K; Dillner J
    Int J Cancer; 2008 Jan; 122(2):372-6. PubMed ID: 17935124
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Screening for cervical cancer with the human papillomavirus test in an area of central Italy with no previous active cytological screening programme.
    Confortini M; Giorgi Rossi P; Barbarino P; Passarelli AM; Orzella L; Tufi MC
    J Med Screen; 2010; 17(2):79-86. PubMed ID: 20660436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa.
    Vijayaraghavan A; Efrusy M; Lindeque G; Dreyer G; Santas C
    Gynecol Oncol; 2009 Feb; 112(2):377-83. PubMed ID: 19081611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-Effectiveness of High-Risk Human Papillomavirus Testing With Messenger RNA Versus DNA Under United States Guidelines for Cervical Cancer Screening.
    Ting J; Smith JS; Myers ER
    J Low Genit Tract Dis; 2015 Oct; 19(4):333-9. PubMed ID: 26225945
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The health and economic effects of HPV DNA screening in The Netherlands.
    Berkhof J; Coupé VM; Bogaards JA; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ
    Int J Cancer; 2010 Nov; 127(9):2147-58. PubMed ID: 20112339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inefficiencies and High-Value Improvements in U.S. Cervical Cancer Screening Practice: A Cost-Effectiveness Analysis.
    Kim JJ; Campos NG; Sy S; Burger EA; Cuzick J; Castle PE; Hunt WC; Waxman A; Wheeler CM;
    Ann Intern Med; 2015 Oct; 163(8):589-97. PubMed ID: 26414147
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States.
    Kim JJ; Ortendahl J; Goldie SJ
    Ann Intern Med; 2009 Oct; 151(8):538-45. PubMed ID: 19841455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost effectiveness of human papillomavirus-16/18 genotyping in cervical cancer screening.
    Huh WK; Williams E; Huang J; Bramley T; Poulios N
    Appl Health Econ Health Policy; 2015 Feb; 13(1):95-107. PubMed ID: 25385310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-Effectiveness of Primary HPV Screening Strategies and Triage With Cytology or Dual Stain for Cervical Cancer.
    Tantitamit T; Khemapech N; Havanond P; Termrungruanglert W
    Cancer Control; 2020; 27(1):1073274820922540. PubMed ID: 32372659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis of human papillomavirus DNA testing and Pap smear for cervical cancer screening in a publicly financed health-care system.
    Chow IH; Tang CH; You SL; Liao CH; Chu TY; Chen CJ; Chen CA; Pwu RF
    Br J Cancer; 2010 Dec; 103(12):1773-82. PubMed ID: 21102588
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more.
    Goldie SJ; Kim JJ; Wright TC
    Obstet Gynecol; 2004 Apr; 103(4):619-31. PubMed ID: 15051550
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy.
    Kim JJ; Wright TC; Goldie SJ
    J Natl Cancer Inst; 2005 Jun; 97(12):888-95. PubMed ID: 15956650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cost-effectiveness analysis on the once-in-a-lifetime cervical cancer screening program for women living in rural and urban areas of China].
    Xu H; Zhao FH; Gao XH; Hu SY; Chen JF; Liu ZH; Xu XL; Gao LM; Liu QG; Ma L; Liu YJ; Qiao YL
    Zhonghua Liu Xing Bing Xue Za Zhi; 2013 Apr; 34(4):399-403. PubMed ID: 23937850
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany.
    Sroczynski G; Schnell-Inderst P; Mühlberger N; Lang K; Aidelsburger P; Wasem J; Mittendorf T; Engel J; Hillemanns P; Petry KU; Krämer A; Siebert U
    GMS Health Technol Assess; 2010 Apr; 6():Doc05. PubMed ID: 21289878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A model to evaluate the costs and clinical effectiveness of human papilloma virus screening compared with annual papanicolaou cytology in Germany.
    Petry KU; Barth C; Wasem J; Neumann A
    Eur J Obstet Gynecol Reprod Biol; 2017 May; 212():132-139. PubMed ID: 28363186
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Costs and effectiveness of alternative strategies for cervical cancer screening in military beneficiaries.
    Maxwell GL; Carlson JW; Ochoa M; Krivak T; Rose GS; Myers ER
    Obstet Gynecol; 2002 Oct; 100(4):740-8. PubMed ID: 12383543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cervical cancer screening among HIV-infected women: an economic evaluation in a middle-income country.
    Vanni T; Luz PM; Grinsztejn B; Veloso VG; Foss A; Mesa-Frias M; Legood R
    Int J Cancer; 2012 Jul; 131(2):E96-104. PubMed ID: 21964797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis.
    Karnon J; Peters J; Platt J; Chilcott J; McGoogan E; Brewer N
    Health Technol Assess; 2004 May; 8(20):iii, 1-78. PubMed ID: 15147611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Present and future of cervical cancer prevention in Spain: a cost-effectiveness analysis.
    Georgalis L; de Sanjosé S; Esnaola M; Bosch FX; Diaz M
    Eur J Cancer Prev; 2016 Sep; 25(5):430-9. PubMed ID: 26375246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The budget impact of cervical cancer screening using HPV primary screening.
    Wright T; Huang J; Baker E; Garfield S; Hertz D; Cox JT
    Am J Manag Care; 2016 Mar; 22(3):e95-105. PubMed ID: 26978241
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.